Vincerx Pharma, Inc. (VINC)
- Previous Close
0.7557 - Open
0.7532 - Bid 0.7352 x 300
- Ask 0.7966 x 200
- Day's Range
0.7500 - 0.8000 - 52 Week Range
0.6100 - 9.3720 - Volume
210,548 - Avg. Volume
1,223,391 - Market Cap (intraday)
22.582M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8900 - Earnings Date May 14, 2024 - May 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
vincerx.comRecent News: VINC
Performance Overview: VINC
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VINC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VINC
Valuation Measures
Market Cap
22.45M
Enterprise Value
12.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.00
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-68.72%
Return on Equity (ttm)
-136.38%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-40.16M
Diluted EPS (ttm)
-1.8900
Balance Sheet and Cash Flow
Total Cash (mrq)
12.78M
Total Debt/Equity (mrq)
22.29%
Levered Free Cash Flow (ttm)
-24.29M
Research Analysis: VINC
Company Insights: VINC
VINC does not have Company Insights